Deal­ing Bio­gen an­oth­er blow, EMA rec­om­mends re­ject­ing Aduhelm in three terse para­graphs

The Eu­ro­pean Med­i­cines Agency an­nounced Fri­day it rec­om­mend­ed the Eu­ro­pean Com­mis­sion re­ject Aduhelm, deal­ing a new — al­beit ex­pect­ed — blow to Bio­gen’s hopes of find­ing a wide­spread mar­ket for its strug­gling Alzheimer’s drug.

The EMA rec­om­men­da­tion had been ex­pect­ed for a month, since the EMA’s hu­man med­i­cines com­mit­tee gave Bio­gen “a neg­a­tive trend vote” af­ter an oral pre­sen­ta­tion from the com­pa­ny. As such Bio­gen’s stock, which has lost all the stratos­pher­ic val­ue it gained af­ter Aduhelm’s ap­proval in June, on­ly ticked down 3% pre-mar­ket Fri­day, from $235.52 to $235.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.